Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$136.84 USD

136.84
1,508,925

+0.32 (0.23%)

Updated Aug 4, 2025 01:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Here's Why You Should Invest in Cooper Companies (COO) Now

by Zacks Equity Research

Cooper Companies (COO) is consistently trying to boost inorganic growth.

    Zacks Equity Research

    Zacks.com featured highlights: Ollie's Bargain Outlet, Dollar Tree, Align Technology and Broadcom

    by Zacks Equity Research

    Zacks.com featured highlights: Ollie's Bargain Outlet, Dollar Tree, Align Technology and Broadcom

      Zacks Equity Research

      Genomic Health (GHDX) Oncotype DX Score Test Data Positive

      by Zacks Equity Research

      Genomic Health (GHDX) forges ahead with development of Oncotype DX Breast Recurrence Score test.

        Zacks Equity Research

        Boston Scientific Receives FDA Nod for Vercise DBS System

        by Zacks Equity Research

        Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.

          Zacks Equity Research

          Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm

          by Zacks Equity Research

          Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.

            Zacks Equity Research

            Hill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife

            by Zacks Equity Research

            Hill-Rom's (HRC) upbeat long-term view buoys optimism.

              Zacks Equity Research

              Inogen Rides on Solid Product Portfolio Amid Forex Woes

              by Zacks Equity Research

              Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.

                Zacks Equity Research

                Omnicell's Rising Costs Affect Bottom Line Amid Competition

                by Zacks Equity Research

                Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.

                  Zacks Equity Research

                  Myriad Genetics Presents Encouraging EndoPredict Test Data

                  by Zacks Equity Research

                  Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.

                    Zacks Equity Research

                    NxStage Nx2me Connected Health Improves Home Hemodialysis

                    by Zacks Equity Research

                    NxStage Medical (NXTM) consistently looks to expand dialysis platform.

                      Tirthankar Chakraborty headshot

                      Buy These 4 Stocks With Excellent Earnings Growth

                      by Tirthankar Chakraborty

                      We have picked stocks that have displayed historical earnings growth and are also seeing a rise in quarterly and annual earnings estimates.

                        Zacks Equity Research

                        Varian Halcyon Gets ANVISA Registration, Grows in Oncology

                        by Zacks Equity Research

                        Varian (VAR) consistently tries to expand in the global market with Halcyon system.

                          Zacks Equity Research

                          Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus

                          by Zacks Equity Research

                          Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.

                            Zacks Equity Research

                            Myriad Genetics (MYGN) Presents Positive riskScore Test Data

                            by Zacks Equity Research

                            Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.

                              Zacks Equity Research

                              Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod

                              by Zacks Equity Research

                              Hologic's (HOLX) recent spree of regulatory approvals for its array of products is encouraging.

                                Zacks Equity Research

                                Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival

                                by Zacks Equity Research

                                Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.

                                  Zacks Equity Research

                                  Walgreens Boots Invests in China to Fortify Retail Pharmacy

                                  by Zacks Equity Research

                                  Walgreens Boots' (WBA) decision to buy a minority stake in Sinopharm Holding Guoda Drugstores is likely to leverage its global pharmacy expertise.

                                    Zacks Equity Research

                                    Edwards Lifesciences Buys Harpoon Medical, Expands Portfolio

                                    by Zacks Equity Research

                                    Edwards Lifesciences (EW) expands Surgical Heart Valve Therapy segment with the buyout of Harpoon Medical.

                                      Zacks Equity Research

                                      Hologic Banks on Molecular Diagnostics, Competition Rife

                                      by Zacks Equity Research

                                      Hologic (HOLX) gains on increasing market share and utilization of fully-automated Panther system.

                                        Zacks Equity Research

                                        Here's Why You Should Invest in PetMed (PETS) Stock Now

                                        by Zacks Equity Research

                                        PetMed's (PETS) implements strategies to revitalize top line. It also offers a comprehensive portfolio.

                                          Zacks Equity Research

                                          IDEXX Laboratories Banks on Global Prospects, CAG Strength

                                          by Zacks Equity Research

                                          IDEXX Laboratories (IDXX) rides on strength across all segments, especially CAG. Strong fundamentals buoy optimism.

                                            Zacks Equity Research

                                            Align Technology Rides High on InvisAlign & Strategic Pacts

                                            by Zacks Equity Research

                                            Rising demand for InvisAlign products in the global teen market and the distribution agreement with Patterson Dental are major upsides for Align (ALGN).

                                              Zacks Equity Research

                                              CVS-Aetna Deal: What's Hot, What's Not

                                              by Zacks Equity Research

                                              CVS Health (CVS) and Aetna consolidation to add a new dimension to healthcare landscape. However, critics believe the gain will be short-lived for the healthcare society.

                                                Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics

                                                by Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics

                                                  Zacks Equity Research

                                                  Quest Diagnostics Banks on Buyouts to Expand in Diagnostic

                                                  by Zacks Equity Research

                                                  Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.